Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Margreet KloppenburgCharles PeterfyIda K HaugenFéline P B KroonSu ChenLi WangWei LiuGwen LevyRoy M FleischmannFrancis BerenbaumDésirée Mfm van der HeijdePrashant BansalRuth WittoekSheng FengYuni FangMary SaltarelliJeroen K MedemaMarc C LevesquePublished in: Annals of the rheumatic diseases (2018)
Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.
Keyphrases
- placebo controlled
- double blind
- clinical trial
- phase iii
- study protocol
- chronic pain
- open label
- rheumatoid arthritis
- high resolution
- pain management
- phase ii
- neuropathic pain
- randomized controlled trial
- squamous cell carcinoma
- spinal cord injury
- skeletal muscle
- metabolic syndrome
- spinal cord
- rectal cancer
- insulin resistance